Hot Features
프리미엄
Biomea Fusion Inc (BMEA)
NASDAQ
브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. 더 보기
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be...
New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight reduction and 43% increase in lean muscle mass...
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response...
REDWOOD CITY, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemiaBMF-500 showed a favorable safety and...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.4699 | 11.8065326633 | 3.98 | 4.59 | 3.8 | 696812 | 4.2970037 | CS |
| 4 | 0.4999 | 12.6556962025 | 3.95 | 4.59 | 3.64 | 825934 | 4.03986043 | CS |
| 12 | -4.5501 | -50.5566666667 | 9 | 9.26 | 3.64 | 863794 | 5.35681629 | CS |
| 26 | -1.0601 | -19.2395644283 | 5.51 | 13.07 | 3.64 | 853776 | 7.07861674 | CS |
| 52 | -12.3001 | -73.4334328358 | 16.75 | 20.21 | 3.61 | 1001078 | 9.16660353 | CS |
| 156 | -2.2301 | -33.3847305389 | 6.68 | 43.69 | 2.84 | 658515 | 14.49245209 | CS |
| 260 | -15.5501 | -77.7505 | 20 | 43.69 | 2.84 | 551838 | 14.38865129 | CS |
Monksdream
5 월 전
Zraced1
8 월 전
giveit2me
1 년 전
Invest-in-America
2 년 전
Invest-in-America
2 년 전
TheFinalCD
2 년 전
Invest-in-America
2 년 전
Bbradley8
2 년 전
